A new trading day began on November 20, 2023, with Avalo Therapeutics Inc (NASDAQ: AVTX) stock priced at $0.0896, down -4.11% from the previous day of trading. During the day, the shares moved up to $0.0905 and dropped to $0.0855 before settling in for the closing price of $0.09. AVTX’s price has ranged from $0.08 to $6.09 over the past 52 weeks.
Healthcare Sector giant saw their annual sales surged by 27.11% over the last five years. Meanwhile, its annual earnings per share averaged 90.97%. With a float of $191.97 million, this company’s outstanding shares have now reached $192.38 million.
The firm has a total of 20 workers. Let’s measure their productivity. In terms of profitability, gross margin is +80.77, operating margin of -207.41, and the pretax margin is -230.62.
Avalo Therapeutics Inc (AVTX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Avalo Therapeutics Inc is 0.22%, while institutional ownership is 0.62%. The most recent insider transaction that took place on Jun 27, was worth 486,888. In this transaction 10% Owner of this company sold 937,404 shares at a rate of $0.52, taking the stock ownership to the 731,458 shares. Before that another transaction happened on Jun 26, when Company’s 10% Owner sold 2,746,138 for $0.61, making the entire transaction worth $1,682,010. This insider now owns 1,668,862 shares in total.
Avalo Therapeutics Inc (AVTX) Earnings and Forecasts
In its latest quarterly report, released on 9/29/2023, the company reported earnings of -$0.11 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). This company achieved a net margin of -230.78 while generating a return on equity of -684.77. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 90.97% per share during the next fiscal year.
Avalo Therapeutics Inc (NASDAQ: AVTX) Trading Performance Indicators
Here are Avalo Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.59, a number that is poised to hit -0.02 in the next quarter and is forecasted to reach -0.07 in one year’s time.
Technical Analysis of Avalo Therapeutics Inc (AVTX)
Analysing the last 5-days average volume posted by the [Avalo Therapeutics Inc, AVTX], we can find that recorded value of 13.59 million was lower than the volume posted last year of 22.59 million. As of the previous 9 days, the stock’s Stochastic %D was 8.85%. Additionally, its Average True Range was 0.01.
During the past 100 days, Avalo Therapeutics Inc’s (AVTX) raw stochastic average was set at 1.80%, which indicates a significant decrease from 2.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.04% in the past 14 days, which was lower than the 192.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.1255, while its 200-day Moving Average is $1.4469. Now, the first resistance to watch is $0.0894. This is followed by the second major resistance level at $0.0924. The third major resistance level sits at $0.0944. If the price goes on to break the first support level at $0.0844, it is likely to go to the next support level at $0.0824. Should the price break the second support level, the third support level stands at $0.0794.
Avalo Therapeutics Inc (NASDAQ: AVTX) Key Stats
With a market capitalization of 16.60 million, the company has a total of 20,249K Shares Outstanding. Currently, annual sales are 18,050 K while annual income is -41,660 K. The company’s previous quarter sales were 240 K while its latest quarter income was -5,230 K.